Back to Results
First PageMeta Content
Piperazines / Pyrimidines / Orphan drugs / Organofluorides / Myeloid leukemia / Chronic myelogenous leukemia / Ponatinib / Philadelphia chromosome / Bcr-Abl tyrosine-kinase inhibitor / Medicine / Oncology / Organic chemistry


Hindawi Publishing Corporation ISRN Oncology Volume 2014, Article ID[removed], 9 pages http://dx.doi.org[removed][removed]Review Article
Add to Reading List

Document Date: 2014-08-14 19:34:33

Open Document

File Size: 1,40 MB

Share Result on Facebook

City

Philadelphia / Article / /

Company

Volume 2014 Hindawi Publishing Corporation / Oncology Hindawi Publishing Corporation / Novartis Pharma / Endocrinology Immunology Research Hindawi Publishing Corporation / Medicine Hindawi Publishing Corporation / Novartis Pharmaceuticals / New England Journal / Cleveland Clinic Journal / Cellular Longevity Hindawi Publishing Corporation / Creative Commons / Wyeth / Netherlands Journal / Treatment Volume 2014 Hindawi Publishing Corporation / Hindawi Publishing Corporation / Bristol-Myers Squibb / The Scientific World Journal Hindawi Publishing Corporation / Diabetes Research Volume 2014 Hindawi Publishing Corporation / Practice Hindawi Publishing Corporation / /

Country

Poland / United States / /

/

Event

FDA Phase / /

Facility

University of Lodz / National Science Center / /

IndustryTerm

therapy of the disease / treatment of imatinib refractory chronic myeloid leukemia / treatment for chronic myeloid leukemia / Therapy of Chronic Myeloid Leukemia / identical binding site / cancer therapy / Cancer Therapeutics / chemical modification / therapy for newly diagnosed chronic myeloid leukemia / chemical properties / leukemia therapy / treatment of chronic myeloid leukemia / /

MedicalCondition

advanced disease / haematological and epithelial cancers / CML blast crisis / blast crisis / human cancers / imatinib-resistant chronic myeloid leukaemia / fatal disorder / leukocytosis / BCR/ABL-dependent leukemias / gout / fatigue / hematologic neoplasms / chronic phase / imatinib refractory chronic myeloid leukemia / leukemias / chronic myeloid leukaemia / inhibitor-resistant chronic myelogenous cells / imatinib mesylate-resistant chronic myelogenous leukemia / acute and chronic myelogenous leukemia / leukemia / acute lymphoblastic leukemias / chromosome-positive leukemias / cancer / human leukemia / disease / Molecular Cancer / myeloid leukemia / Tumour / Introduction Chronic myeloid leukemia / chromosome-positive chronic myelogenous leukemia / targeted cancer / chronic disease / diseases / chronic myelogenous leukemia / Ph-chromosome-positive leukemia / AIDS / few malignant diseases / Chronic Myeloid Leukemia / human chronic granulocytic leukemia / thyroid cancer / acute myeloid leukemia / Chronic Phase Chronic Myeloid Leukemia / /

MedicalTreatment

chemotherapy / cancer therapy / /

Organization

National Science Center / National Academy of Sciences / TNF-R / Ewelina Trela / Sylwester Glowacki / and Janusz BBasiak Department of Molecular Genetics / American Society of Hematology / US Food and Drug Administration / University of Lodz / Faculty of Biology and Environmental Protection / /

Person

B. Comin-Anduix / D. Canuti / D. Niino / J. Jelinek / V / /

Position

mediator / /

Product

Gleevec / cytarabine / Siemens S45 Cellular Phone / Tasigna / DCC-2036 / /

ProvinceOrState

Aurora / British Columbia / /

PublishedMedium

Molecular and Cellular Biology / Journal of Clinical Investigation / Cancer Research / The FASEB Journal / Proceedings of the National Academy of Sciences / PLoS ONE / The New England Journal of Medicine / Journal of Clinical Oncology / /

Technology

alpha / Pharmacogenomic / drug metabolism / stem cells / apoptosis / Epigenomics / gene expression / chemotherapy / treating cancer / http / /

URL

http /

SocialTag